Trials in advanced Hodgkin's disease: More than 30 years experience of the British National Lymphoma Investigation

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 174-183

  Zekri, Jamal M ^a   Mouncey, Paul ^b   Hancock, Barry W ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b British Natl Lymphoma Investigation   (United Kingdom)

Author keywords

Alternating regimens; Bleomycin; Combined modality treatment; Hybrid chemotherapy; MOPP chemotherapy; Radiation therapy

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAINTENANCE THERAPY; NAUSEA; OUTCOMES RESEARCH; PHLEBITIS; SECOND CANCER; SENSITIVITY ANALYSIS; VOMITING;

EID: 13644271067     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.023     Document Type: Article

References (62)

1. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73:881-895.
2. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.
3. Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306:770-775.
4. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104:739-746.
5. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-1484.
6. Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990; 62:279-285.
7. Cullen MH, Stuart NS, Woodroffe C, et al. ChlVPP/P0ABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. J Clin Oncol 1994; 12:779-787.
8. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3:1174-1182.
9. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hy0b0rid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21:607-614.
10. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15:1638-1645.
11. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. Ann Oncol 1991; 2(suppl 2):55-62.
12. Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16:19-26.
13. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
14. Horning SJ, Hoppe RT, Breslin S, et al. Stanford vs. and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630-637.
15. Roemaekers J, Burgers J, Henry-Amar M, et al. Involved field radiotherapy for patients in partial remission after MOPP/ABV chemotherapy in stage III-IV Hodgkin's disease: results from the EORTC lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie phase III trial (protocol 20884). In: Proceedings of the Third International Symposium on Hodgkin's lymphoma; September 18-23, 1995; Cologne, Germany.
16. Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9:2193-2201.
17. Loeffler M, Brosteanu O, Hasenclever D, et 0al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818-829.
18. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396-2406.
19. Goldman JM. Combination chemotherapy for stage IV Hodgkin's disease (Report no 14). Clin Radiol 1981; 32:531-536.
20. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease - long term results. Br J Cancer 1991; 63:579-582.
21. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol 1992; 10:1252-1258.
22. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol 1994; 5(suppl 2):117-120.
23. Hancock BW, Gregory WM, Cullen MH, et al. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer 2001; 84:1293-1300.
24. Sweetenham JW, Smith P, MacMillan A, et al. Stanford vs. versus ABVD for adult patients with advanced Hodgkin's disease: Preliminary results of a randomised trial from the BNLI. Fifth International Symposium on Hodgkin's Lymphoma. Leuk Lymphoma 2001; 42(suppl 2):57.
25. Johnson PM, Radford J, Cullen MH, et al. Randomised Comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): initial results of the UKLG LY09 study (ISRCTN 97144519). Blood 2003; 102:27a (Abstract #84).
26. Strickland P. Radiotherapy or chemotherapy as the initial treatment for stage IIIA Hodgkin's disease (Report no 13). Clin Radiol 1981; 32:527-530.
27. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation studies of pathological stage IIIA Hodgkin's disease: long term follow up. No Role for Nodal Irradiation? Br J Cancer 1990; 62(suppl 11):9.
28. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1051-1054.
29. Jacobs C, Portlock CS, Rosenberg SA. Prednisone in MOPP chemotherapy for Hodgkin's disease. Br Med J 1976; 2:1469-1471.
30. Coltman CA, Delaney FC. Five drug combination chemotherapy for advanced Hodgkin's disease (HD). Clin Res 1973; 31:876
31. Young RC, Canellos GP, Chabner BA, et al. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet 1973; 1:1339-1343.
32. Diggs CH, Wiernik PH, Levi JA, et al. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease. Cancer 1977; 39:1949-1954.
33. Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet 1975; 2:1224-1247.
34. Dusenbery KE, Peterson BA, Bloomfield CD. Chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for Hodgkin disease: fourteen-year follow-up results. Am J Hematol 1988; 28:246-251
35. Cooper MR, Pajak TF, Nissen NI, et al. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 1980; 46:654-662.
36. McElwain TJ, Toy J, Smith E, Peckham MJ, et al. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 36:276-280.
37. Nissen NI, Pajak TF, Glidewell O, et al. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Cancer 1979 43:31-40.
38. Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990; 62:279-285.
39. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27-37.
40. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66:439-449.
41. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial J Clin Oncol 1994; 12:279-287.
42. Gams RA, Durant JR, Bartolucci AA. Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group. Cancer Treat Rep 1982; 66:899-905.
43. Vinciguerra V, Propert KJ, Coleman M, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4:838-846.
44. Longo DL, Duffey PL, DeVita VT Jr, et al. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9:1409-1420.
45. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20:2988-2994.
46. Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13:2379-2385.
47. Viviani S, Bonfante V, Santoro A, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999; 5:275-282.
48. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81:1137-1145.
49. Gianni AM, Siena S, Bregni M, et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - a 6-year update. Ann Oncol 1993; 4:889-891.
50. Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9:1871-1879.
51. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193-1199.
52. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7:179-185.
53. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065-2071.
54. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89:814-822.
55. Radman I, Basic N, Labar B, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002; 13:1650-1655.
56. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17:534-545.
57. Czyz J, Hellmann A, Dziadziuszko R, et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30:29-34.
58. Bloomfield CD, Pajak TF, Glicksman AS, et al. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 1982; 66:835-846.
59. Grozea PN, Depersio EJ, Coltman CA Jr, et al. Chemotherapy alone versus combined modality theapy for stage III Hodgkin's disease; a five-year follow-up of a Southwest Oncology Group study (SWOG-7518). Proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland. 1984; 2:892-897.
60. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120:903-912.
61. Glick JH, Barnes JM, Bakemeier RF, et al. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group. Cancer Treat Rep 1982; 66:855-870.
62. Pavlovsky S, Santarelli MT, Muriel FS, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease. Ann Oncol 1992; 3:533-537.